Femasys Inc. Announces the Appointment of Wendy Perrow, Transformational Biotech Entrepreneur, as New Board Member
Femasys Inc. (NASDAQ: FEMY) has appointed Wendy Perrow to its board of directors, bringing extensive experience in fundraising and corporate strategy. Perrow's background includes leadership roles in several biotechnology companies, notably raising $31 million for Alba Therapeutics. This announcement coincides with the resignation of William Witte, who served since 2017. The leadership change comes at a crucial time as Femasys prepares for pivotal trials for its product candidates FemBloc and FemaSeed. Perrow aims to leverage her expertise to enhance the company's growth in women's reproductive health.
- Wendy Perrow's appointment brings extensive experience in fundraising and corporate strategy.
- Ms. Perrow has a proven track record in life sciences, which may aid Femasys in upcoming clinical trials.
- The board change occurs as Femasys gears up for crucial trials for its product candidates, potentially enhancing investor confidence.
- William Witte's resignation may raise concerns about continuity and experience on the board.
Industry leader Wendy Perrow brings decades of expertise in fundraising, global product launches and corporate strategy to the Femasys team
ATLANTA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the appointment of a new board member, Wendy Perrow. Ms. Perrow brings decades of experience in the life sciences industry related to fundraising, global product launches and corporate strategy. Additionally, Femasys announced that William Witte, a board member since 2017 has resigned.
“We are thrilled to have Wendy join our board and be able to tap into her experience at a key time, as we progress with our de novo clinical trial for FemaSeed®, our localized directional insemination product candidate for infertility, and, just as we gear up for the pivotal trial later this year for our permanent birth control product candidate, FemBloc®," Kathy Lee-Sepsick, president, chief executive officer and founder of Femasys, commented. “Wendy brings to the board a strong and proven track record of topline vision and corporate strategy, as well as high-level tactical expertise in marketing, business and product development and fundraising. All of which will prove to be incredibly beneficial as we steer Femasys forward with our commercial assets in tandem with the clinical progression of our lead product candidates.”
Ms. Lee-Sepsick added, “I would also like to express our gratitude to William Witte for his time and support while a board member over the past four years. William was instrumental in assisting with fund raising prior and during our initial public offering. His over 28 years’ experience in the financial and capital markets was crucial to our strategic planning and execution as we entered and became acclimated in the public markets.”
Ms. Perrow brings a proven record of company-building and fundraising, in addition to corporate strategy, business and product development, regulatory, manufacturing and marketing in the life sciences. Most recently, Ms. Perrow was the chief executive officer of AsclepiX Therapeutics, Inc., an early-stage biotechnology company developing novel peptide therapeutics for indications in retinal diseases and oncology. She also served as an AsclepiX board member. Prior to this, Ms. Perrow was the chief executive officer of Alba Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapeutics for autoimmune and gastrointestinal diseases. During this time. Ms. Perrow was instrumental in raising
Throughout her career, Ms. Perrow has led the creation of companies focused on ophthalmology and oncology, and she has launched world-renowned products in cholesterol, vaccines, and hypertension yielding multi-billion dollars in sales, as well as closed a multi-million dollar out-licensing deal for a first-of-its kind phase 2 asset. Ms. Perrow additionally has diverse global business experience working with the U.S., European, Pan-Asian and Latin American markets.
Ms. Perrow commented, “I am excited to be joining the Femasys Board at a time when we are in a position to leverage the company’s lead product candidates, FemBloc and FemaSeed, pre-market. My background lies in maximizing value for breakthrough assets with novel mechanisms of action, so I am eager to be able to offer my expertise and contribute to maximizing the value of these product candidates as they progress towards potential commercialization, as well as maximize the company’s overall corporate strategy as it matures following its entry in the public markets.”
Ms. Perrow received her MBA in Finance and Marketing from Duke University, The Fuqua School of Business and has an undergraduate degree, magna cum laude, in Education from Eastern Illinois University. Ms. Perrow sits on several boards and is a member of Women in Bio.
About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s product for fallopian tube assessment by ultrasound, FemVue®, is currently marketed in the United States. Femasys is also advancing FemCerv®, a technology platform for tissue sampling intended to be marketed alongside its other women-specific medical products in the physician’s office setting.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “believe,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 11, 2021, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
+1-917-741-7792
chuck@lifesciadvisors.com
Media
Sky Striar
LifeSci Communications
sstriar@lifescicomms.com
Femasys Inc.
Investor Contact:
IR@femasys.com
Media Contact:
Media@femasys.co
FAQ
What new developments were announced by Femasys on January 20, 2022?
How does Wendy Perrow's background benefit Femasys?
What are Femasys's key product candidates mentioned in the press release?
